MADRID—BioNTech’s new manufacturing process for CAR-T seems to have done the trick in boosting the potency of the solid tumor therapy BNT211, but that bit of extra juice appears to have upped the side ...

For some cases of cancer, the starting point of a new treatment is already inside the patient. Cell therapy provides another option for advanced blood cancers that have not responded to other drugs.

At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...

According to Kite, the median turnaround time for Yescarta is expected to be reduced from 16 days to 14 days. The Food and Drug Administration (FDA) has approved a manufacturing process change for ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

For patients with certain types of cancer, CAR T cell therapy has been nothing short of life changing. Developed in part by Carl June, Richard W. Vague Professor at Penn Medicine, and approved by the ...

The FDA has approved a manufacturing change that is expected to reduce the median turnaround time for Yescarta to 14 days. The US Food and Drug Administration (FDA) has approved a manufacturing ...